{"originalText": "，2012-6肠镜示直乙交界占位（距肛门10-15CM），印戒细胞癌。盆腔MRI提示子宫附件占位，，肿标：CA724 10.77，，CA125:112,2012-7-4行乙状结肠癌切除+两侧附件占位切除，术中肿物固定于前方膀胱后壁、盆腔侧壁，具体不详。7-19始行XELOX+泰欣生600MG*8周期，末次化疗2012-12-20。 自2013-1-11单药希罗达1.5G BID D1-14 Q3W+泰欣生600MG/周维持治疗中。 2013-5-20，多学科会诊：建议盆腔放疗，同时联合泰欣生治疗。放疗前可以继续希罗达1.5G BID D1-14 Q3W+泰欣生600MG/周治疗。 现进食、体力可，无明显不适，一般情况可。放疗计划50GY/25次，2013-6-14开始放疗，2013.7.18放疗结束。现乏力，腰酸，食欲差，大便可，无便血。", "entities": [{"end_pos": 20, "label_type": "解剖部位", "overlap": 0, "start_pos": 18}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 29, "end_pos": 34}, {"label_type": "影像检查", "overlap": 0, "start_pos": 35, "end_pos": 40}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 42, "end_pos": 44}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 44, "end_pos": 46}, {"label_type": "实验室检验", "overlap": 0, "start_pos": 53, "end_pos": 58}, {"label_type": "实验室检验", "overlap": 0, "start_pos": 66, "end_pos": 71}, {"label_type": "手术", "overlap": 0, "start_pos": 85, "end_pos": 101}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 111, "end_pos": 113}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 116, "end_pos": 118}, {"end_pos": 141, "label_type": "药物", "overlap": 0, "start_pos": 138}, {"end_pos": 182, "label_type": "药物", "overlap": 0, "start_pos": 179}, {"end_pos": 204, "label_type": "药物", "overlap": 0, "start_pos": 201}, {"end_pos": 238, "label_type": "解剖部位", "overlap": 0, "start_pos": 236}, {"end_pos": 248, "label_type": "药物", "overlap": 0, "start_pos": 245}, {"end_pos": 261, "label_type": "药物", "overlap": 0, "start_pos": 258}, {"end_pos": 283, "label_type": "药物", "overlap": 0, "start_pos": 280}, {"end_pos": 360, "label_type": "解剖部位", "overlap": 0, "start_pos": 359}]}
